Oragenics Inc. Announces Strategic Financial Move to Advance Neurological Disorder Treatments

Oragenics Inc. (NYSE American: OGEN), a leader in the development of intranasal pharmaceuticals for neurological disorders, has taken a decisive step toward advancing its research and development initiatives. The company has announced an agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, with each unit priced at $25.00. This move is designed to generate gross proceeds of up to $20 million, which will be allocated toward several key areas. These include the progression of the ONP-2 concussion trials, the support of ongoing R&D efforts, the repayment of a $3 million bridge note, and the coverage of general corporate expenses.

The offering's structure includes Warrants that provide the holder with the option to purchase an additional Preferred share at the same $25.00 price. Notably, the Preferred shares are convertible into common stock at $2.50 per share. Dawson James Securities, Inc. has been appointed as the sole placement agent for this transaction, which is expected to be finalized around July 2, 2025. This financial strategy is crucial for Oragenics as it aims to enhance its capabilities in treating mild traumatic brain injury (mTBI), also known as concussion, and other neurological conditions through its pioneering nasal delivery pharmaceuticals.

This development is a testament to Oragenics' dedication to tackling the challenges posed by neurological and infectious diseases. The funding secured through this offering is not just a milestone for the company but also represents a beacon of hope for patients awaiting innovative treatments. For more information on this significant financial maneuver, interested individuals can refer to the detailed press release available here. The initiative underscores the critical role of financial investment in pushing the boundaries of medical science and improving patient outcomes in the field of neurology.